【摘要】 目的探讨胰高糖素样肽1(GLP-1)类似物对2型糖尿病合并肥胖患者腹部脂肪的影响。方法选取45例初诊2型糖尿病合并肥胖患者,在二甲双胍治疗的基础上联合GLP-1类似物治疗6个月,观察治疗前后FBG、TG、LDL-C、HbA1c、腰围、BMI、空腹胰岛素(FIns)、高敏C肽蛋白、HOMA-IR及腹部脂肪体积(VAA)、内脏脂肪体积(VVA)及皮下脂肪体积(VSA)的变化。结果治疗6个月后,患者HOMA-IR、腰围、BMI、FBG、HbA1c、FIns、高敏C肽蛋白、TG、LDL-C水平及VAA、VVA和VVA/VSA均低于治疗前(P<0.05)。Pearson相关分析显示,VAA与BMI、腰围、LDL-C、HbA1c、FIns、高敏C肽蛋白和HOMA-IR呈正相关(r=0.769、0.867、0.765、0.535、0.497、0.655和0.532,P<0.05)。结论 GLP-1类似物治疗可降低2型糖尿病合并肥胖患者血糖水平、减轻体重和减少内脏脂肪含量。更多还原

【Abstract】 Objective To explore the effect of glucagon-like peptide-1(GLP-1)analogue on abdominal fat of type 2 diabetes mellitus(T2 DM)patients with obesity.Methods On the basis of metformin treatment,45 newly diagnosed T2 DM patients with obesity were treated additionally with GLP-1 analogue for 6 months.The FBG,TG,LDL-C,HbA1 c,waist circumference(WC),BMI,FIns,high sensitivity C-peptide protein(hsCPP),HOMA-IR,volume of abdominal adipose(VAA),volume of visceral adipose(VVA)and volume of subcutaneous adipose(VSA)were measured before and after treatment.Results The levels of FBG,HbA1 c,FIns,hsCPP,TG,LDL-C,WC,BMI,HOMA-IR and VAA,VVA,VVA/VSA were lower after 6 months treatment than those before(P<0.05).Pearson correlation analysis showed that VAA was positively correlated with BMI,WC,LDL-C,HbA1 c,FIns,hsCPP and HOMA-IR(r=0.769,0.867,0.765,0.535,0.497,0.655 and 0.532,P<0.05).Conclusion In the T2 DM patients with obesity,treatment with GLP-1 analogue can effectively reduce the glucose level,body weight and visceral adipose tissue volume.更多还原